The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | The challenges of using CAR-T cell therapy to treat patients with CLL
In this video, Thomas J Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, discusses the challenges of treating patients with chronic lymphocytic leukemia (CLL) effectively with CAR-T cell therapy. Dr Kipps first comments on the importance of patient selection for CAR-T therapy, the challenges of managing therapy-related toxicities, and then goes on to discuss ongoing studies in this space and the promise of CAR-T cells in the treatment of CLL. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
